Milestone Scientific Inc., a leading developer of computerized drug delivery instruments that provide painless and precise injections based in Roseland, announced the appointment of Eric C. Hines as chief executive officer, effective immediately.
Hines brings more than 25 years of leadership experience in scaling sales-driven enterprise software companies, serving customers across a range of industries, including health care.
Most recently, he served as president of North America at Ex Libris, a division of Clarivate, where he led operations across the U.S., Canada and Latin America, and increased annual revenue from approximately $50 million to over $100 million. Additionally, he launched multiple new product lines; managed marketing, sales and service organizations; and drove new customer expansion.
Hines also held executive positions at NICE Systems, where he led a North American security business exceeding $90 million, and previously served in the customer experience management (CEM) division, overseeing both the central and western regions, as well as channel sales and customer experience management.
Throughout his career, Hines has consistently built high-performance teams, delivered top-line growth and led commercial expansions into new geographies and industry verticals. He holds a B.A. in chemistry from Wake Forest University and an MBA in international business from Xavier University.
“We are pleased to welcome Eric as CEO,” Said Neal Goldman, chairman of the board of Milestone Scientific. “His leadership experience growing complex, commercially disciplined organizations will be critical as we work to accelerate the adoption of our CompuFlo technology. We have made meaningful progress on the reimbursement front, including the assignment of Medicare Part B payment rates under CPT code 0777T across multiple jurisdictions, as well as initial commercial insurance payments. We believe Eric is the right executive to build on this foundation, expand our presence in the medical and dental markets, and guide the company as we pursue new clinical indications and global opportunities.”
“I am honored to lead Milestone Scientific at such a pivotal moment for the company,” said Hines. “During my diligence, I was impressed by the strength of the CompuFlo platform, the clinical validation supporting its use and the company’s recent reimbursement achievements, including favorable Medicare payment rates. These milestones create a strong base for expanded commercial adoption. I also see compelling opportunities in the dental segment, where Milestone’s STA system remains highly differentiated, and in extending the CompuFlo technology into new indications and international markets.
“Having worked closely with customers across a range of industries, including health care, I appreciate the importance of technologies that deliver both clinical and economic value. I look forward to working with the team to execute on these priorities and deliver long-term value for our stakeholders.”
